Ideas to action: independent research for global prosperity
Women's Underrepresentation in IFI Leadership
November 27, 2023
EU-Africa Strategy: State of Play
November 24, 2023
A New Grand Bargain to Improve the Antimicrobial Market for Human Health
September 20, 2023
In our final working group report, we outline the principles of a Grand Bargain that we believe all stakeholders can and should sign up to during the UN General Assembly's High-Level Meeting on antimicrobial resistance in 2024. Explore our recommendations on increasing the availability of critically...
Taking Stock of Organizations with Impact Evaluation Capacity Headquartered in sub-Saharan Africa: A New Database and Landscaping Analysis
August 07, 2023
CGD conducted a landscaping exercise to better understand the current landscape of organizations headquartered in sub-Saharan Africa that boast impact evaluation capacity. The resulting database is intended as a resource for funders looking to advance locally led development; to help facilitate coor...
The World Bank Should Harness Evidence to Deliver Greater Impact
June 05, 2023
The World Bank’s lending function is important and irreplaceable. But providing countries with an important source of financing and investing in evidence do not have to be in tension. The role of evaluation should shift from an assessment function to one in which evaluation is a central tool of pro...
A Dual Evidence Agenda: Delivering Greater Impact for Development and Global Challenges
March 20, 2023
With global challenges high on the international agenda and financing set to increase in the coming years, a big push on evidence, backed by dedicated resources, is essential. This note makes the case for a reinvigorated evidence agenda to boost the impact of financing for development and global pub...
The Future of Global Health Spending Amidst Multiple Crises
January 17, 2023
This CGD note summarizes the implications of the macroeconomic context and broader financing outlook for domestic and external health spending and proposes a “menu” of policy options to keep health spending on track and blunt negative impacts on health systems and population health around the world.
Developing an Omni-Channel Deployment Strategy for COVID-19 Oral Antivirals
December 14, 2022
Ensuring rapid and equitable access to effective oral COVID-19 therapies is essential to reducing health disparities from COVID-19 and building a better response system for future epidemics and pandemics. A multipronged strategy for medical countermeasures must include antivirals, monoclonal antibod...
Oral Antiviral Treatments for COVID-19: Time to Revisit?
December 14, 2022
Almost a year after two oral antiviral treatments received emergency use authorization, demand is extremely low. In this note, we argue that governments and their donor partners should use data and evidence to consider the economic and clinical rationale for registering, financing, purchasing, and d...